APT will offer a broad portfolio and oral drug delivery technology platforms, including Bioavailability, as well as enhanced and customized drug release.
| PALM DESERT, Calif., Feb. 28, 2019 /PRNewswire/ -- HealthMed Services, Ltd., (OTC Pink – HEME – News) announced today that it has entered into a Memorandum of Understanding to form a Joint Venture between Advanced Prenatal Therapeutics, Inc. (APT) and a new distribution company, to be formed by HealthMed to distribute products that have been invented and.or patented by APT. Dr. James Smith. Ph. D said, “APT has several patents either granted or pending that cover a broad range of Apheresis technology for the treatment of preeclampsia. Preeclampsia is a leading cause of prematurity and intrauterine growth restriction which leads to lifelong challenges for a baby. It is also the leading cause of maternal illness, and approximately 20% of maternal deaths.” Dr. Smith went on to say, “Approximately 10,000 babies die each year in the U.S., and approximately 500,000 worldwide from preeclampsia and we are looking forward in establishing a new distribution company that will JV with HealthMed Services Advanced Prenatal to distribute various products of APT.” (See www.advancedprenatal.com) James Shipley, President of HealthMed Services, Ltd., said, “APT will offer a broad portfolio and oral drug delivery technology platforms, including Bioavailability, as well as enhanced and customized drug release. APT’s flexible technology platforms will enable the new Joint Venture and its distribution partners to provide customized drug formulation solutions across a range of dosage forms and therapies.” Mr. Shipley went on to say, “We are looking forward to building a broad global distribution company and working with Dr. James Smith.” About HealthMed Services Ltd. HealthMed Services, Ltd., (“HEME” or the “Company”) is expanding its business plan and adding to its portfolio various products to include promising new technologies, including medical solutions, that can be commercialized, manufactured, and distributed within a fairly short period of time. Forward Looking Information This press release may contain forward-looking statements about the Company, including descriptions of plans or objectives of its management for future operation, products or services, and forecasts of its revenues, earnings or other measures of economic performance. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include the words, “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” Forward-looking statements, by their nature, are subject to risks and uncertainties. A number of factors – many of which are beyond the Company’s control-could cause actual condition, events or results to differ significantly form those described in the forward-looking statement. Forward-looking statements speak only as of the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date forward looking statements are made. Contact Person:
SOURCE Healthmed Services, Ltd. |
Company Codes: OTC-PINK:HEME |
View original content:
